An interventional study of Active Brainsway H7-Coil Deep TMS System and Sham Brainsway H1-Coil Deep TMS System in Mild Cognitive Impairment (MCI) and Subjective Cognitive Decline (SCD), sponsored by Rotman Research Institute at Baycrest. Recruiting at 1 site in Canada. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-10-28.
Sponsored by Rotman Research Institute at Baycrest · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 224 studies in Cognitive Dysfunction with a site in Canada — 61 open to participants now, 80 under way, 7 of them phase 3. Cognitive Dysfunction · Canada.
Among the 224 studies in Cognitive Dysfunction with a site in Canada, this one is the 120th largest by planned enrollment of the 171 interventional ones that give a count, is one of 24 that started in 2025, is one of 116 with no phase, reaches primary completion later than 44 of the 79 other live ones, and was the 213th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →61 of the 224 studies in Cognitive Dysfunction with a site in Canada are open now. Recruiting first, the newest first:
Posit Science Corporation · Sites in Canada
Ages 65+
Laval University · Sites in Canada
Ages 60+
Qanatpharma AG · Sites in Canada
Ages 18+
Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal · Sites in Canada
Ages 50–80 · Healthy volunteers
University of British Columbia · Sites in Canada
Ages 50–80 · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 55 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
224 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 29 · Phase 3 21 · Phase 4 3
First in 1999; this study’s year is marked. 24 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 64 across the 171 interventional studies, 353 across the 52 observational. Of the 121 that completed or were terminated, 17 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 224 have an industry lead sponsor. The 10 most frequent:
Rotman Research Institute at Baycrest is the lead sponsor of 11 studies on the registry; 4 are open to participants now.
Rotman Research Institute at Baycrest has 3 studies filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
24 of the studies in Cognitive Dysfunction with a site in Canada that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05230758Phase 3Donald MabbottEffect of Metformin on Behaviour and the Brain in Children Treated for a Brain Tumour | 2027-11-30 |
| NCT06529744University Health Network, TorontoImproving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling | 2026-11 |
| NCT04335994Sunnybrook Health Sciences CentreENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing | 2026-12 |
| NCT06783283Centre for Addiction and Mental HealthTACS to Engage Theta-Gamma Coupling and Enhance Working Memory in Patients With MCI (tACS-MCI) | 2026-12 |
Add all 24 to your calendar (.ics) → With an account.
Among the 224 studies in Cognitive Dysfunction with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to test whether an accelerated deep Transcranial Magnetic Stimulation (dTMS) protocol in combination with cognitive training can improve cognitive abilities in older adults with Subjective Cognitive Decline (SCD) or Mild Cognitive Impairment (MCI). The study will look at whether it is safe and tolerable to use accelerated dTMS to enhance the benefits of cognitive training in older adults, and will also gather early information on the effects of accelerated dTMS on memory and other cognitive abilities.
This study will examine the effects of combining cognitive remediation with accelerated intermittent theta burst stimulation (a-iTBS) using the H7 deep Transcranial Magnetic Stimulation (dTMS) coil to target the anterior cingulate cortex (ACC) in older adults aged 55-85 with MCI or SCD. Thirty older adults will participate in a single site, double-blind, randomized sham-controlled trial using an accelerated schedule of multiple dTMS sessions per day for 2-5 consecutive days, followed by 6 weeks of online cognitive remediation for both sham and dTMS interventions. The primary goal of the study is to establish the feasibility of an a-iTBS protocol combined with cognitive training in older adults with Mild Cognitive Impairment (MCI) and Subjective Cognitive Decline (SCD) and to obtain preliminary evidence of treatment efficacy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Active Brainsway H7-Coil Deep TMS System
Device: Sham Brainsway H1-Coil Deep TMS System
Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel dTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions. dTMS will be administered 6-8 times a day for 2-5 consecutive days.
In addition to the active H7-coil, a sham coil is included in the H1-coil helmet.The sham treatment will be administered using the H1-coil helmet 6-8 times a day for 2-5 consecutive days.
Percentage of dTMS sessions attended by participants
Time frame: 1 week
Incidence and type of of adverse events experienced during treatment (participant-reported tolerability) based on the Adverse Events Questionnaire (AEQ)
The AEQ asks about symptoms related immediately after TMS administration where patients rate symptom severity from 1 (absent) to 4 (severe) and whether they believe it is related to TMS from 1 (no) to 5 (definitely).
Time frame: 9 weeks
The number of participants who prematurely withdraw and reasons for withdrawal
Time frame: 9 weeks
Change from baseline memory scores on computerized neuropsychological battery following the final session on day 5
Memory score from memory tests in the neuropsychological battery at baseline will be compared to after 5 days of TMS and after 6 weeks of cognitive training the active intervention group compared to the sham. A higher memory score indicates better memory performance. An effect size (Cohen's d) of 0.5 will be considered a minimally important effect size.
Time frame: 9 weeks
Change from baseline executive function scores on computerized neuropsychological battery following final session on day 5
Executive function scores from tests on the neuropsychological battery will be compared from baseline to after days of dTMS and after 6 weeks of cognitive training in the active intervention group compared to sham. A higher score on these tests indicate greater executive functioning. An effect size (Cohen's d) of 0.5 will be considered a minimally important effect size.
Time frame: 9 weeks
The change in baseline in scores on the Geriatric Anxiety Inventory (GAI) following 5 days of dTMS
The GAI is a 20-item self-report measure of anxiety developed for older adults. Administration time is approximately 5 minutes. The GAI scores range from 0-20, with higher scores indicating more anxiety.
Time frame: 1 week
The change in resting state activity as measured with electroencephalography (EEG) following 5 days of dTMS
Time frame: 1 week
The change in slow wave activity in the posterior default mode network (posterior cingulate cortex) as measured with MEG following 5 days of dTMS
Time frame: 1 week
The change in functional connectivity within the default mode network based on Magnetic Resonance Imaging (MRI) following 5 days of dTMS
Time frame: 1 week
The change in baseline in scores on the Geriatric Depression Scale (GDS)
GDS is a 15-item self-report scale that measures an elderly individual's mood. A score greater than 5 suggests that the individual may be depressed. Administration time is approximately 5 minutes. GDS scores range from 0-15 with a greater score indicating greater depressive symptoms.
Time frame: 1 week
The change in baseline slow wave as measured with electroencephalography (EEG) following 5 days of dTMS
Time frame: 1 week
Start is estimated for Nov 2025; primary completion for Mar 2027, 16 months later.
Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 16 months is below that.
Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rotman Research Institute at Baycrest